A recent study demonstrated the superiority of lorlatinib over crizotinib as the first-line treatment in patients with advanced ALK-positive NSCLC.15 Also, lorlatinib showed favorable efficacy in patients with advanced ROS1-rearranged NSCLC, including crizotinib-pretreated patients and those with CNS metastases.16 This evidence concerns the gene ROS1 and non-small cell lung carcinoma.